secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2026-10-08T20:05:15+00:00
Accession:  0001104659-26-114695
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07
LLM model:  deepseek-v4.1-flash:cloud@v2

TELA Bio holders approve 1-for-5 to 1-for-15 reverse split; no split planned after Nasdaq compliance regained
--------------------------------------------------------------------------------

- Special Meeting held October 8, 2026; 45,143,410 common shares outstanding as of the September 8, 2026 record date.
- Proposal 1 approved: 30,515,571 votes for, 80,512 against, 1,737,011 abstentions, 0 broker non-votes.
- Amendment would combine shares at a ratio of not less than one-for-five and not more than one-for-fifteen, exact ratio set by the Board in its sole discretion.
- Proposal 2 (adjournment if needed) approved: 30,757,679 for, 123,860 against, 1,451,555 abstentions.
- October 5, 2026 Nasdaq letter stated the company regained compliance with Listing Rule 5450(a)(1) minimum bid price; TELA Bio does not intend to effect the reverse split at this time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926114695/0001104659-26-114695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926114695/tm2627202d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-114695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer